Cytosorbents Corporation
CTSO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 14.5% | -10.4% | -13.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 70.6% | 70.6% | 59.8% | 72.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -42.7% | -89.7% | -86.5% | -53.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -58.2% | -94.1% | -94.6% | -61.2% |
| EPS Diluted | -0.38 | -0.65 | -0.75 | -0.57 |
| % Growth | 41.5% | 13.3% | -31.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |